INTERNATIONAL ALLIED HEALTH CONFERENCE 2024: A GLOBAL PLATFORM FOR HEALTHCARE COLLABORATION
Singapore hosts landmark event uniting over 1,100 Allied Health Professionals and students from around the world SINGAPORE, Nov. 1, 2024 /PRNewswire/ -- The International Allied Health Conference (IAHC 2024), which was held in conjunction with the third Singapore Allied Health Conference on 1 November 2024, brought together about 1,100 global Allied Health...
The 1-Year Follow-up Results of LuX-Valve Plus were Officially Released at TCT 2024
WASHINGTON, Nov. 1, 2024 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases with TTVR breakthroughs, has just released the 1-year outcome of LuX-Valve Plus TRAVEL II study at 2024 Transcatheter Cardiovascular Therapeutics Conference (TCT 2024) by on October 29th in Washington,...
DX&VX Selected for Korea’s First ARPA-H Project in 2024, Focusing on Room Temperature and Extra-Long-Term Vaccine Storage Technology
Pioneering Korea's ARPA-H Project: Focused on mRNA Vaccine Room-Temperature Storage and Extra-Long-Term Preservation Creating a Platform for Prolonged Room-Temperature Storage and Efficient Distribution of mRNA Vaccines SEOUL, South Korea, Nov. 1, 2024 /PRNewswire/ -- On October 30, a Korean Biotech company, DX&VX(www.dxvx.com; KOSDAQ 180400, Majority shareholder Lim Chong-yoon) announced its selection as a co-research institution...
The Phase III clinical trial application for first-line treatment of extensive disease small cell lung cancer with Chiauranib has been approved
SHENZHEN, China, Nov. 1, 2024 /PRNewswire/ -- On November 1, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Biosciences") and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceutical Ltd., received the "Drug Clinical Trial Approval Notice" approved by the National Medical Products Administration. The company's self-developed original new drug, Chiauranib, combined with PD - (L) 1 monoclonal antibody and...
HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business Update
HanAll records revenue of 36.8 billion KRW in the third quarter, with an operating profit of 430 million KRW. Results for the Phase 1 study in healthy subjects for HL192 (ATH-399A), a novel compound targeting Parkinson's Disease, are expected in November 2024. ROCKVILLE, Md. and SEOUL, South Korea, Nov. 1,...
ICANN81 in Istanbul to Address Future of Global Internet Governance
ISTANBUL, Nov. 1, 2024 /PRNewswire/ -- The Internet Corporation for Assigned Names and Numbers (ICANN) will hold its 81st Public Meeting in Istanbul from 9-14 November 2024, hosted by the Information and Communication Technologies Authority (BTK). This event will bring together in-person and virtual participants from around the world to discuss important...
Senhwa Biosciences Announces the Appointment of Dr. Yiu-Lian Fong, the Former Global Head of Janssen Diagnostic Innovation and R&D at Johnson & Johnson as the New Corporate Director
TAIPEI and SAN DIEGO, Nov. 1, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced the appointment of Dr. Yiu-Lian Fong to the board of directors for Ding Li Development Ltd. Dr. Fong, a present...
PharmaResearch Hosts 5th Global Symposium on ‘Rejuran’
Over 600 Medical Professionals from 25 Countries Participate Launch of 'IRC' Committee for Rejuran Global Research Team SEONGNAM, South Korea, Nov. 1, 2024 /PRNewswire/ -- PharmaResearch (CEO Ki Seock Kang and Thinkyou Kim) announced today that it successfully held the 5th PharmaResearch Global Symposium (PGS) at the Lakai Sandpine Resort on October 28-29, 2024. This year's event attracted...
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab
HONG KONG, Nov. 1, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the AK112-309 trial, a randomized, controlled, multicenter Phase III registration study for biliary track tumor. This trial is designed to compare the ivonescimab combined regimen, a PD-1/VEGF bispecific antibody internally developed by Akeso, with the durvalumab...
National Comprehensive Cancer Network Joins with Vietnam National Cancer Hospital to Enhance Cancer Treatment
International collaboration meets in Vietnam to facilitate treatment recommendation guidelines that help people with cancer to live better lives. HANOI, Vietnam, Nov. 1, 2024 /PRNewswire/ -- As part of ongoing work to define and advance high-quality cancer care globally, leaders from the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer...
